GlaxoSmithKline announced that the US Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour of Impax Laboratories Inc, and upheld a lower court ruling that Impax's generic product did not infringe GSK's US patent for its antidepressant Wellbutrin SR.
GSK continues to be committed to Wellbutrin XL - its once daily version of Wellbutrin launched last fall -- which now represents nearly 40 per cent of new prescriptions being written for Wellbutrin (XL & SR).